Article

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Functional training (FT) and resistance exercise (RE) improved functional capacity, functional status, disease activity, and muscle strength to a comparable extent in patients with psoriatic arthritis (PsA).

Major finding: FT and RE led to similar improvements in functional capacity measured by the Bath Ankylosing Spondylitis Functional Index (P = .919), functional status measured by the Health Assessment Questionnaire for the Spondyloarthropathies (P = 0.932), disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = .700), and muscle strength in patients with PsA. No adverse event occurred in either group.

Study details: Findings are from a 12-week, single-blind trial that included 41 patients with PsA who were randomly assigned to undergo FT with elastic bands or RE with weight machines.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Silva DR et al. Effectiveness of functional training versus resistance exercise in patients with psoriatic arthritis: Randomized controlled trial. Adv Rheumatol. 2023;63:58. (Dec 13). doi: 10.1186/s42358-023-00342-y

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Adults with pre-existing psoriatic arthritis (PsA) who underwent surgery for lumbar degenerative disease (LDD) faced increased odds of unfavorable discharge and venous thromboembolism (VTE) events compared with those without PsA.

Major finding: A diagnosis of PsA in patients who underwent LDD surgery increased the odds of unfavorable discharge by 26% (adjusted odds ratio [aOR] 1.26; 95% CI 1.03-1.55) and nearly doubled the risk for VTE (aOR 1.99; 95% CI 1.05-3.75).

Study details: This population-based retrospective study included 467,814 patients (age ≥ 20 years) who underwent surgery for LDD, of whom 883 patients had pre-existing PsA and were matched to 8830 patients without PsA.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Chen MY et al. Psoriatic arthritis increases the risk of venous thromboembolism following degenerative lumbar spine surgery: An analysis of U.S. Nationwide Inpatient Sample 2005–2018. Heliyon. 2023;10(1):E23613 (Dec 12). doi: 10.1016/j.heliyon.2023.e23613

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Female patients with psoriatic arthritis (PsA) who received tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) showed lower treatment persistence than male patients with PsA who received the same therapeutic class of drugs.

Major finding: Women demonstrated 20%-40% lower treatment persistence rates than men for TNFi (adjusted hazard ratio [aHR] 1.4; 99% CI 1.3-1.5) and IL-17i (aHR 1.2; 99% CI 1.1-1.3) therapies; however, the treatment persistence between both sexes was comparable for IL12/23i (aHR 1.1; 99% CI 0.9-1.3), IL23i (aHR 1.1; 99% CI 0.7-1.5), and Janus kinase inhibitor (aHR 1.2; 99% CI 0.9-1.6) therapies.

Study details: This nationwide cohort study included 14,778 patients with PsA who were new users of targeted therapies, of whom 57% were women and 43% were men.

Disclosures: This study did not receive any specific grant. Two authors declared receiving subsidy or consulting fees from or being an investigator for various pharmaceutical companies. Other authors declared no conflicts of interest.

Source: Pina Vegas L et al. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: A cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9:e003570 (Dec 19). doi: 10.1136/rmdopen-2023-003570

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Although Psoriatic Arthritis Impact of Disease questionnaire-12 items (PsAID-12) scores were higher in patients with psoriatic arthritis (PsA) who did vs did not have a treatment escalation, physicians relied more on their assessment of disease activity while making treatment-related decisions.

Major finding: Higher mean PsAID-12 score correlated with higher odds of treatment escalation in patients with PsA (odds ratio [OR] 1.58; P < .0001), whereas physician’s assessment of disease activity had the most significant impact on likelihood of treatment escalation (OR 2.68; P < .0001). Longer disease duration, treatment with nonbiologics, and a higher swollen joint count also increased the odds for treatment escalation.

Study details: Findings are from a cross-sectional analysis (the ASSIST study) that included 503 patients with PsA (age ≥ 18 years), of whom 160 patients underwent treatment escalation.

Disclosures: This study was funded by Amgen, and the National Institute for Health Research Oxford Biomedical Research Centre. Several authors declared receiving grants, honoraria, consultancy fees, or travel support from or having ties with various sources, including Amgen.

Source: Coyle C et al. How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2024 (Jan 8). doi: 10.1093/rheumatology/kead679

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z

Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.

Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).

Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.

Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.

Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z

Key clinical point: Even though disease-free survival (DFS) outcomes were comparable in patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), the degree of nodal involvement affected prognostic outcomes in both these populations.

Major finding: In patients with ILC vs IDC, DFS was similar in the overall population (P = .743), but it was significantly worse (pN2/pN3; adjusted hazard ratio [aHR] 1.40; P = .033) and better (pN0/pN1; aHR 0.60; P = .005) in patients with extensive and limited nodal involvement, respectively.

Study details: Findings are from a pooled analysis of three phase 3 trials, SUCCESS A, B, and C, which included 7236 intermediate-to-high risk patients with IDC (n = 6284) or ILC (n = 952) and who received adjuvant chemotherapy.

Disclosures: The SUCCESS trials were supported by AstraZeneca, Sanofi-Aventis, and other sources. Two authors declared receiving honoraria from various sources unrelated to this work. Other authors declared no conflicts of interest.

Source: Dayan D et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: Results from the SUCCESS trials. Breast Cancer Res. 2023;25:153 (Dec 14). doi: 10.1186/s13058-023-01750-0

Key clinical point: Even though disease-free survival (DFS) outcomes were comparable in patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), the degree of nodal involvement affected prognostic outcomes in both these populations.

Major finding: In patients with ILC vs IDC, DFS was similar in the overall population (P = .743), but it was significantly worse (pN2/pN3; adjusted hazard ratio [aHR] 1.40; P = .033) and better (pN0/pN1; aHR 0.60; P = .005) in patients with extensive and limited nodal involvement, respectively.

Study details: Findings are from a pooled analysis of three phase 3 trials, SUCCESS A, B, and C, which included 7236 intermediate-to-high risk patients with IDC (n = 6284) or ILC (n = 952) and who received adjuvant chemotherapy.

Disclosures: The SUCCESS trials were supported by AstraZeneca, Sanofi-Aventis, and other sources. Two authors declared receiving honoraria from various sources unrelated to this work. Other authors declared no conflicts of interest.

Source: Dayan D et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: Results from the SUCCESS trials. Breast Cancer Res. 2023;25:153 (Dec 14). doi: 10.1186/s13058-023-01750-0

Key clinical point: Even though disease-free survival (DFS) outcomes were comparable in patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), the degree of nodal involvement affected prognostic outcomes in both these populations.

Major finding: In patients with ILC vs IDC, DFS was similar in the overall population (P = .743), but it was significantly worse (pN2/pN3; adjusted hazard ratio [aHR] 1.40; P = .033) and better (pN0/pN1; aHR 0.60; P = .005) in patients with extensive and limited nodal involvement, respectively.

Study details: Findings are from a pooled analysis of three phase 3 trials, SUCCESS A, B, and C, which included 7236 intermediate-to-high risk patients with IDC (n = 6284) or ILC (n = 952) and who received adjuvant chemotherapy.

Disclosures: The SUCCESS trials were supported by AstraZeneca, Sanofi-Aventis, and other sources. Two authors declared receiving honoraria from various sources unrelated to this work. Other authors declared no conflicts of interest.

Source: Dayan D et al. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: Results from the SUCCESS trials. Breast Cancer Res. 2023;25:153 (Dec 14). doi: 10.1186/s13058-023-01750-0

Key clinical point: A molecular subtype-guided treatment based on four triple-negative breast cancer (TNBC) subtypes nearly doubled progression-free survival (PFS) outcomes compared with control therapy with nab-paclitaxel and had a favorable safety profile in patients with metastatic TNBC.

Major finding: Patients who received nab-paclitaxel + subtype-based therapy vs only nab-paclitaxel had significantly longer progression-free survival (median 11.3 months vs 5.8 months; hazard ratio 0.44; P < .0001). Neutropenia (30% vs 23%), anemia (7% vs none), and increased alanine aminotransferase (6% vs 1%) were the most common types of grade 3-4 treatment-related adverse events in the subtype-based group vs control group.

Study details: Findings are from the ongoing phase 2 FUTURE-SUPER trial that included 139 women age 18-70 years with metastatic or recurrent TNBC who were randomly assigned to receive a nab-paclitaxel + subtype-based regimen or only nab-paclitaxel.

Disclosures: This study was supported by Jiangsu Hengrui Pharmaceuticals, the National Key Research and Development Project of China, and other sources. Two authors declared being employees of Jiangsu Hengrui Pharmaceuticals.

Source: Fan L et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024 (Jan 8). doi: 10.1016/S1470-2045(23)00579-X

Key clinical point: A molecular subtype-guided treatment based on four triple-negative breast cancer (TNBC) subtypes nearly doubled progression-free survival (PFS) outcomes compared with control therapy with nab-paclitaxel and had a favorable safety profile in patients with metastatic TNBC.

Major finding: Patients who received nab-paclitaxel + subtype-based therapy vs only nab-paclitaxel had significantly longer progression-free survival (median 11.3 months vs 5.8 months; hazard ratio 0.44; P < .0001). Neutropenia (30% vs 23%), anemia (7% vs none), and increased alanine aminotransferase (6% vs 1%) were the most common types of grade 3-4 treatment-related adverse events in the subtype-based group vs control group.

Study details: Findings are from the ongoing phase 2 FUTURE-SUPER trial that included 139 women age 18-70 years with metastatic or recurrent TNBC who were randomly assigned to receive a nab-paclitaxel + subtype-based regimen or only nab-paclitaxel.

Disclosures: This study was supported by Jiangsu Hengrui Pharmaceuticals, the National Key Research and Development Project of China, and other sources. Two authors declared being employees of Jiangsu Hengrui Pharmaceuticals.

Source: Fan L et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024 (Jan 8). doi: 10.1016/S1470-2045(23)00579-X

Key clinical point: A molecular subtype-guided treatment based on four triple-negative breast cancer (TNBC) subtypes nearly doubled progression-free survival (PFS) outcomes compared with control therapy with nab-paclitaxel and had a favorable safety profile in patients with metastatic TNBC.

Major finding: Patients who received nab-paclitaxel + subtype-based therapy vs only nab-paclitaxel had significantly longer progression-free survival (median 11.3 months vs 5.8 months; hazard ratio 0.44; P < .0001). Neutropenia (30% vs 23%), anemia (7% vs none), and increased alanine aminotransferase (6% vs 1%) were the most common types of grade 3-4 treatment-related adverse events in the subtype-based group vs control group.

Study details: Findings are from the ongoing phase 2 FUTURE-SUPER trial that included 139 women age 18-70 years with metastatic or recurrent TNBC who were randomly assigned to receive a nab-paclitaxel + subtype-based regimen or only nab-paclitaxel.

Disclosures: This study was supported by Jiangsu Hengrui Pharmaceuticals, the National Key Research and Development Project of China, and other sources. Two authors declared being employees of Jiangsu Hengrui Pharmaceuticals.

Source: Fan L et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024 (Jan 8). doi: 10.1016/S1470-2045(23)00579-X

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: Higher levels of leisure-time physical activity reduced the risk for premenopausal breast cancer (BC) significantly, with more prominent effects observed for human epidermal growth factor receptor 2 (HER2)-enriched BC.

Major finding: At a median follow-up of 11.5 years, higher vs lower levels (90^th vs 10^th percentile) of leisure-time physical activity were associated with a 10% reduced risk for overall BC (adjusted hazard ratio [aHR] 0.90; P < .001) and a substantial 45% reduction in the risk for HER2-enriched BC (aHR 0.55; 95% CI 0.37-0.82).

Study details: Findings are from a pooled analysis of the data from 19 prospective cohorts that included a total of 547,601 premenopausal women with 10,231 incident cases of in situ or invasive BC.

Disclosures: This study was supported by the Intramural Research Program of the US National Cancer Institute and US National Institutes of Health, and other sources. Some authors declared employment with; holding patents, stocks, and other ownership interests in; serving in consulting or advisory roles for; or receiving honoraria or research funding from various sources.

Source: Timmins IR et al. International pooled analysis of leisure-time physical activity and premenopausal breast cancer in women from 19 cohorts. J Clin Oncol. 2023 (Dec 11). doi: 10.1200/JCO.23.01101

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: In patients with human epidermal growth factor receptor 2-negative (HER2−) inflammatory breast cancer (BC), the estrogen receptor-positive (ER+)/progesterone receptor-negative (PR−) vs ER+/PR+ phenotype was associated with significantly worse survival outcomes.

Major finding: Patients with ER+/PR‒ vs ER+/PR+ phenotype had significantly worse BC-specific survival (hazard ratio [HR] 1.764; P < .001) and overall survival (HR 1.675; P < .001) outcomes.

Study details: This retrospective study analyzed the data of 1553 women with ER+/HER2− inflammatory BC from the Surveillance, Epidemiology, and End Results (SEER) database, of whom 25.5% and 74.5% of patients presented with ER+/PR− and ER+/PR+ phenotypes, respectively.

Disclosures: This study was supported by grants from the North Sichuan Medical College Scientific Research and Development Project and Guigang Science and Technology Project. The authors declared no conflicts of interest.

Source: Luo Y et al. ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer. Sci Rep. 2024;14:197 (Jan 2). doi: 10.1038/s41598-023-50755-4

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791

Key clinical point: Combining radiotherapy with pyrotinib and capecitabine led to improved intracranial survival outcomes and an acceptable radiation necrosis rate in patients with human epidermal growth factor receptor 2-positive (ERBB2+) breast cancer (BC) with brain metastases.

Major finding: The 1-year central nervous system (CNS) progression-free survival (PFS) rate was 74.9% (95% CI 61.9%-90.7%), and the median CNS PFS was 18.0 months (95% CI 15.5-not reached). Diarrhea (7.5%) was the most common grade ≥ 3 treatment-related adverse event. Asymptomatic radiation necrosis was identified in only 6% of the 67 lesions treated with fractionated stereotactic radiotherapy.

Study details: Findings are from a phase 2 trial that included 40 women with ERBB2+ BC and brain metastases who received fractionated stereotactic or whole-brain radiotherapy and initiated treatment with pyrotinib and capecitabine.

Disclosures: This study was supported by the National Natural Science Foundation of China (NSFC). Three authors declared receiving grants or personal fees from various sources, including the NSFC.

Source: Yang Z et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 2024 (Jan 4). doi: 10.1001/jamaoncol.2023.5791